Subcutaneous semaglutide 2.4 mg injection (Wegovy®) is a GLP-1 receptor agonist (GLP1-RA) approved for the treatment of obesity and overweight with ≥1 weight-related disease in Canada [19]. Here, GLP1R is linked to Obesity.